The "Chronic Kidney Disease (CKD) - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
The "Chronic Kidney Disease (CKD) - Pipeline Insight, 2020," report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Chronic Kidney Disease pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Chronic Kidney Disease Emerging Drugs Chapters
This segment of the Chronic Kidney Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic Kidney Disease Emerging Drugs
AstraZeneca is conducting a study to evaluate the dose-response efficacy, safety, and pharmacokinetics (PK) of AZD5718 in participants with proteinuric chronic kidney disease. The study will be conducted in approximately 118 study centers across 12 countries. The overall study period will be around 28 weeks. Approximately 632 participants comprising of 67% diabetic kidney disease (DKD) and 33% non-DKD participants will be enrolled.
DDO-3055: Jiangsu HengRui Medicine Co., Ltd.
Jiangsu HengRui Medicine is conducting a randomized, double-blind, dose-escalating, placebo controlled, phase I study to evaluate the safety and pharmacokinetics and pharmacodynamics of DDO-3055 in healthy volunteers and patients with Chronic Kidney Disease.
This is a randomized, double-blind, dose-escalating, placebo controlled, Phase I study to evaluate the safety, pharmacokinetics and pharmacodynamics of DDO-3055 in healthy volunteers and patients with chronic kidney disease. 48 healthy volunteers will be enrolled in Part A, and 18 patients with chronic kidney disease will be enrolled in Part B.
Chronic Kidney Disease: Therapeutic Assessment
This segment of the report provides insights about the different Chronic Kidney Disease drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Chronic Kidney Disease
There are approx. 50+ key companies which are developing the therapies for Chronic Kidney Disease. The companies which have their Chronic Kidney Disease drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, AstraZeneca, UnicoCell Biomed, Jiangsu Hansoh Pharmaceutical, Bio Sidus, Keryx Biopharmaceuticals, AMAG Pharmaceuticals, inRegen, AbbVie etc.
The report covers around 50+ products under different phases of clinical development like
Mid-stage products (Phase II and Phase I/II)
Early-stage products (Phase I/II and Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Proteins and peptides
The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Kidney Disease R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Kidney Disease.
August 2020: DAPA-CKD trial meets primary endpoint in patients with chronic kidney disease. Dapagliflozin reduces the risk of kidney failure, death from cardiovascular causes or heart failure hospitalisation and all-cause mortality in chronic kidney disease patients with or without type 2 diabetes. That's the main result of the DAPA-CKD trial presented in a Hot Line session today at ESC Congress 2020.
Chronic Kidney Disease Report Insights
Chronic Kidney Disease Pipeline Analysis
Impact of Drugs
Chronic Kidney Disease Report Assessment
Pipeline Product Profiles
Inactive drugs assessment
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Chronic Kidney Disease drugs?
How many Chronic Kidney Disease drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Kidney Disease?
What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Kidney Disease therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Chronic Kidney Disease and their status?
What are the key designations that have been granted to the emerging drugs?
Allena Pharmaceuticals Inc
apceth Biopharma GmbH
Arch Biopartners Inc
Astellas Pharma Inc
BiOrion Technologies BV
Boehringer Ingelheim GmbH
Boryung Pharmaceutical Co Ltd
Certa Therapeutics Pty Ltd
Conatus Pharmaceuticals Inc
Corvidia Therapeutics Inc
DiaMedica Therapeutics Inc
Dimerix Bioscience Pty Ltd
Epigen Biosciences Inc
Galectin Therapeutics Inc
GNI Group Ltd
Isarna Therapeutics GmbH
KBP BioSciences Co Ltd
Klotho Therapeutics Inc
Les Laboratoires Servier SAS
NovaTarg Therapeutics Inc
Novo Nordisk AS
OPKO Health Inc
Otsuka Holdings Co Ltd
Q BioMed Inc
Redx Pharma Plc
Regulus Therapeutics Inc
Sanwa Kagaku Kenkyusho Co Ltd
Sarfez Pharmaceuticals Inc
Scholar Rock Inc
Sphaera Pharma Pte Ltd
Symic Biomedical Inc
Taisho Pharmaceutical Holdings Co Ltd
Theravance Biopharma Inc
Unity Biotechnology Inc
Vascular Biogenics Ltd
VESSL Therapeutics Ltd
Vicore Pharma AB
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/2ahta6
View source version on businesswire.com: https://www.businesswire.com/news/home/20210513005763/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900